bfgf scios-nova solution (ph 5) in 9% sucrose, sodium citrate and edta  (Scios Nova Inc)

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Variations of bFGF concentration with incubation time up to 72 h in the acellular medium supplemented with ( a ) the non-lyophilized (white triangles) or lyophilized (black triangles) F12 membrane, or ( b ) 10 ng/mL of free bFGF (average ± SD; n = 3; * p < 0.05).

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques: Concentration Assay, Incubation

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Variations of bFGF concentration with incubation time up to 72 h in the acellular medium supplemented with the lyophilized F2, F4, F8, and F12 membranes (average ± SD; n = 3).

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques: Concentration Assay, Incubation

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: ( a ) Concentrations of bFGF in the culture medium of human iPSCs on Days 1, 2, and 3, in the medium-change-free continuous culture with the lyophilized F4 membrane (F4 group; gray bars) or F12 membrane (F12 group; black bars), or in standard culture using the bFGF-containing medium with daily medium refreshment (control group; white bars) (average + SD; n = 3; * p < 0.05), and ( b ) phase contrast microscopic images of human iPSCs on Days 1 and 3 in the control, F4, and F12 groups.

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques:

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Concentrations of bFGF in the culture medium of human iPSCs, on Day 3 in repeated (up to 5 times) cycles of the medium-change-free continuous culture with the lyophilized F4 membrane (F4 group; gray bars) or of standard culture using bFGF-containing medium with daily medium refreshment (control group; white bars) (average + SD; n = 3; * p < 0.05).

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques:

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Phase contrast (leftmost column) and fluorescence (right 3 columns) microscopic images of human iPSCs after repeated (5 times) cycles of medium-change-free continuous culture with the lyophilized F4 membrane (F4 group; upper 2 rows) or of standard culture using bFGF-containing medium with daily medium refreshment (control group; lower 2 rows). The iPSCs were stained with FITC (green)-conjugated anti-Nanog, anti-Oct 3/4, and rBC2LCN, and their nuclei were counterstained with DAPI (blue). Insets show higher magnification images.

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques: Fluorescence, Staining

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Variations of bFGF concentration with incubation time up to 72 h in acellular medium supplemented with the lyophilized and cryopreserved [( a ) 0, ( b ) 1, ( c ) 3 months] F4 membrane (average ± SD; n = 3).

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques: Concentration Assay, Incubation

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Concentrations of bFGF in the culture medium of human iPSCs on Days 1, 2, and 3 in medium-change-free continuous culture with the lyophilized and cryopreserved (3 months) F4 membrane (F4 group; gray bars) or in standard culture using bFGF-containing medium with daily medium refreshment (control group; white bars) (average + SD; n = 3; * p < 0.05).

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques:

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: ( a ) Viability of iPSCs and ( b ) relative number of viable iPSCs on Day 3 in medium-change-free continuous culture with the lyophilized and cryopreserved (3 months) F4 membrane (F4 group) or in standard culture using bFGF-containing medium with daily medium refreshment (control group) (average + SD; n = 3; * p < 0.05).

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques:

Journal: Materials

Article Title: Storable bFGF-Releasing Membrane Allowing Continuous Human iPSC Culture

doi: 10.3390/ma14030651

Figure Lengend Snippet: Phase contrast (leftmost column) and fluorescence (right 3 columns) microscopic images of human iPSCs on Day 3 in medium-change-free continuous culture with the lyophilized and cryopreserved (3 months) F4 membrane (F4 group; upper 2 rows) or in standard culture using bFGF-containing medium with daily medium refreshment (control group; lower 2 rows). The iPSCs were stained with FITC (green)-conjugated anti-Nanog, anti-Oct 3/4, and rBC2LCN, and their nuclei were counterstained with DAPI (blue). Insets show higher magnification images.

Article Snippet: The bFGF adsorption process was carried out by immersing the plasma-treated membrane (plasma-treated surface down) in 1 mL of the bFGF solution at 25 °C for 24 h under shaking at 200 rpm with a shaking incubator (DWMaxM BR-104P; TAITEC CORPORATION, Koshigaya, Japan).

Techniques: Fluorescence, Staining